Alnylam Pharmaceuticals Announces the Termination of its RNAi Collaboration with Merck
News Sep 20, 2007
Alnylam Pharmaceuticals, has announced that Merck & Co., Inc. ("Merck") and Alnylam have mutually agreed to terminate their July 2006 amended and restated RNAi agreement.
As a result, Alnylam has rescinded all grants of its intellectual property related to current and future Merck development programs, including the partnership's former co-development programs.
"It is fundamentally in our best interests to terminate our Merck collaboration," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam. "We wish our colleagues at Merck the best of luck in their efforts."
CRISPR Causes More Genome Damage Than First ThoughtNews
Researchers have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.